Content by GAI

With market pressures from generic drug manufacturers at an all-time high, firms have turned to what’s known as “pay for delay,” a stalling tactic employed by originator pharmaceutical manufacturers to maintain market share after a pharmaceutical patent has expired or has been found to be invalid in court.